MADRIGAL PHARMACEUTICALS, INC. 4

Director Daniel J. Brennan received an award of 404 RSU shares and an option to purchase 681 shares of Madrigal Pharmaceuticals, Inc. common stock as part of director compensation.

On June 17, 2026, Director Daniel J. Brennan of Madrigal Pharmaceuticals, Inc. received an equity compensation package consisting of 404 shares of common stock in the form of restricted stock units and a stock option to purchase 681 shares of common stock at an exercise price of $499.86 per share, both awards vesting in full on the earlier of June 17, 2027 or the date of the company’s 2027 annual meeting, contingent on continued service. These are non‑open‑market, board-approved grants, increasing his direct holdings to 1,371 shares of common stock (including the new RSUs) and 681 option shares, representing routine director compensation rather than a discretionary purchase or sale.

Filing Facts

CIK

1157601

Ticker

MDGL

Form

4

Source Type

sec

Accession

0001628280-26-044290

Alert Tier

5